Back to results
US 12,723,063 B2Granted
GIPR-agonist compounds
AssigneeEli Lilly and Company
InventorsJorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
Claims4
A compound comprising SEQ ID NO:10 or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.